FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Liquidia Corporation LQDA

Promising (early)   broader-coverage candidate · Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling cri

On FrontierLab's discovery record since 2026-08-05 (8 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-15), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)2233.6%
Gross margin92.5%
Gross profits / assets0.8
Rule of 402271
Net margin37.4%
Cash runway (months)—
PEG—
Price / sales12.9

Quality checklist

Fundamentals — snapshot as of 2026-09-15

StageEarly
Share issuance (YoY)18.5% · heavy issuance
Moat—
TAM—
P/E (trailing)47.7
EPS (trailing)$1.37
Burn multiple—
Gross-margin trend (pts)22.1
Cash / assets0.54
Net debt / EBITDA-0.9
Statements as ofQ2 FY2026 · filed 2026-08-12

Momentum context — a snapshot from 2026-09-15, not current

Price at surface$65.31 (as of 2026-09-15)
52-week range$21.15 – $93.61
% off 52-wk high-30.2%
RSI (14)36
Relative volume0.9×

Risk flags

Heavy dilution (~19%/yr) — top-decile share issuers have historically underperformed.Hyper-expansion — assets up ~103% in a year; aggressive expanders have historically lagged.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-15 (end-of-day). How grades are computed →